Biomea Fusion Inc. (BMEA) is set to hold a conference call and webcast shortly, scheduled for 8:00 am EST, to unveil the topline findings from its COVALENT-111 study. This clinical trial, now in its phase I/II, explores the potential of their investigational drug, Icovamenib, aimed at treating type 2 diabetes.
Icovamenib distinguishes itself as an oral, highly potent, and selective covalent inhibitor of menin—a crucial transcriptional regulator involved in beta cell growth in the pancreas and oncogenic signaling across various cancers.
The phase I segment of the COVALENT-111 trial, which focused on the administration of Icovamenib to healthy individuals in single ascending dose groups, has concluded. The ongoing phase II involves multiple ascending dose groups, targeting adult patients whose type 2 diabetes remains unmanageable with standard treatments. Following the completion of the Escalation phase, the study advanced into an Expansion Phase (phase IIb), characterized by extended dosing durations for various cohorts of type 2 diabetes patients.
Today, the company will disclose the topline data from the phase IIb section of the trial, encompassing results from 26 weeks of treatment in roughly 200 patients with type 2 diabetes.
The financial markets responded favorably; BMEA shares closed Monday's trading session at $5.85, marking a 3.72% rise. In premarket activity today, the stock has surged an additional 25%, reaching $7.36.
The material has been provided by InstaForex Company - www.instaforex.com
Icovamenib distinguishes itself as an oral, highly potent, and selective covalent inhibitor of menin—a crucial transcriptional regulator involved in beta cell growth in the pancreas and oncogenic signaling across various cancers.
The phase I segment of the COVALENT-111 trial, which focused on the administration of Icovamenib to healthy individuals in single ascending dose groups, has concluded. The ongoing phase II involves multiple ascending dose groups, targeting adult patients whose type 2 diabetes remains unmanageable with standard treatments. Following the completion of the Escalation phase, the study advanced into an Expansion Phase (phase IIb), characterized by extended dosing durations for various cohorts of type 2 diabetes patients.
Today, the company will disclose the topline data from the phase IIb section of the trial, encompassing results from 26 weeks of treatment in roughly 200 patients with type 2 diabetes.
The financial markets responded favorably; BMEA shares closed Monday's trading session at $5.85, marking a 3.72% rise. In premarket activity today, the stock has surged an additional 25%, reaching $7.36.
The material has been provided by InstaForex Company - www.instaforex.com